Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isothiocyanate SCHEMBL22394167 | 0.95 | SMN1; SMN2 (0.44) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 | |
| SCHEMBL4002577 | 0.94 | KEAP1 (0.47) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 | |
| SCHEMBL838431 | 0.88 | CYP1A2 (0.51) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 | |
| SCHEMBL31528856 | 0.82 | HRH3 (0.46) | SMN1; SMN2CYP1A2NAAASIGMAR1MAPK1 | |
| SCHEMBL17211992 | 0.81 | KEAP1 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 | |
| SCHEMBL6946106 | 0.81 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 | |
| SCHEMBL15253474 | 0.81 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 | |
| SCHEMBL3997403 | 0.80 | HRH3 (0.50) | KEAP1SMN1; SMN2CYP1A2NAAASIGMAR1 | |
| SCHEMBL6604869 | 0.78 | TRPA1 (0.45) | KEAP1NAAASIGMAR1ALDH1A1MIF | |
| SCHEMBL23465167 | 0.78 | CYP1A2 (0.46) | KEAP1SMN1; SMN2HPGDDUSP3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409995-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | GLYPHIC BIOTECHNOLOGIES, INC. | 2024-12-12 | — | — | US | claimed |
| CN-118542940-B | Lysosome-targeted AIE photodynamic nanoparticle as well as preparation method and application thereof | 深圳大学 | 2024-11-19 | — | — | CN | claimed |
| CN-118542940-A | Lysosome-targeted AIE photodynamic nanoparticle as well as preparation method and application thereof | 深圳大学 | 2024-08-27 | — | — | CN | claimed |
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3383376-B1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-05-12 | — | — | EP | claimed |
| EP-2736520-B1 | COMPOSITIONS CONTAINING ZINC SALTS AND ISOTHIOCYANATES FOR REDUCTION OF ORAL VOLATILE SULFUR COMPOUNDS (VSCS) | WRIGLEY W M JUN CO (US) | 2020-09-09 | — | — | EP | claimed |
| EP-3383378-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| EP-3383376-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| WO-2017095995-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2017095993-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| CN-103717225-B | Compositions containing zinc salts and isothiocyanates for reducing oral volatile sulfur compounds (VSCs) | WM.雷格利 JR.公司 | 2016-09-28 | — | — | CN | claimed |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| US-20140294739-A1 | COMPOSITIONS CONTAINING ZINC SALTS AND ISOTHIOCYANATES FOR REDUCTION OF ORAL VOLATILE SULFUR COMPOUNDS (VSCs) | WM. WRIGLEY JR. COMPANY (US) | 2014-10-02 | — | — | US | claimed |
| EP-2736520-A2 | COMPOSITIONS CONTAINING ZINC SALTS AND ISOTHIOCYANATES FOR REDUCTION OF ORAL VOLATILE SULFUR COMPOUNDS (VSCS) | Wm. Wrigley Jr. Company (US) | 2014-06-04 | — | — | EP | claimed |
| WO-2013015979-A2 | COMPOSITIONS CONTAINING ZINC SALTS AND ISOTHIOCYANATES FOR REDUCTION OF ORAL VOLATILE SULFUR COMPOUNDS (VSCS) | WM. WRIGLEY JR. COMPANY (US) | 2013-01-31 | — | — | WO | claimed |
| EP-4701635-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | Universitat De Barcelona (ES) | 2026-03-04 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | KEAP1 790/4885SMN1; SMN2 4815/4885HPGD 3624/4885 |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, BHMT, PNMT | KEAP1 167/4885SMN1; SMN2 2360/4885HPGD 1559/4885 |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | CRAT, CPT1A, CPT1B | KEAP1 78/4885SMN1; SMN2 1141/4885HPGD 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.